Paradoxical rise of hemolytic complement in the blood of mice during zymosan- and liposome-induced CARPA: A pilot study

European Journal of Nanomedicine

Volumn 7, Issue 3, 2015, Pages 257-262

  Mészáros, Tamás ^a   Szénási, Gábor ^a,b   Rosivall, László ^a,b   Szebeni, János ^a,c,d   Dézsi, László ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF MISKOLC   (Hungary)

^d SeroScience Ltd   (Hungary)

Author keywords

anaphylatoxins; anaphylaxis; ApoE; complement; hypersensitivity reactions

Indexed keywords

CHEMICAL ACTIVATION; MAMMALS;

ANAPHYLATOXINS; ANAPHYLAXIS; APOE; COMPLEMENT; HYPERSENSITIVITY REACTION;

BLOOD;

AMPHOTERICIN B LIPID COMPLEX; ANAPHYLATOXIN; APOLIPOPROTEIN E; COMPLEMENT; DOXORUBICIN; ZYMOSAN;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY LEAK SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DOG; HEMOCONCENTRATION; HEMOLYSIS; MALE; MOUSE; NONHUMAN; PIG; PILOT STUDY; SHEEP ERYTHROCYTE;

EID: 84931090679     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2015-0022     Document Type: Article

References (22)

1. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
2. Nath P, Basher A, Harada M, Sarkar S, Selim S, Maude RJ, et al. Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Trop Doct 2014;44:241-2.
3. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14:1430-7.
4. Sato M, Sano H, Iwaki D, Kudo K, Konishi M, Takahashi H, et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosaninduced NF-kappa B activation and TNF-Alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol 2003;171:417-25.
5. Szebeni J, Alving CR, Rosivall L, Bunger R, Baranyi L, Bedocs P, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 2007;17:107-17.
6. Dezsi L, Szenasi G, Urbanics R, Rosivall L, Szebeni J. Cardiopulmonary and hemodynamic changes in complement activation-related pseudoallergy. Health 2013;5:1032-8.
7. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 2012;8:176-84.
8. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216:106-21.
9. Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, et al. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J 2011;25:2447-55.
10. Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 2001;286:164-70.
11. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-6.
12. Committee for Human Medicinal Products (CHMP). Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product (Final), EMA/CHMP/806058/2009/Rev.02. (2013); URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/03/WC500140351.pdf. Accessed on February 21, 2013.
13. Szebeni J, Bedocs P, Csukas D, Rosivall L, Bunger R, Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 2012;64:1706-16.
14. Dezsi L, Fulop T, Meszaros T, Szenasi G, Urbanics R, Vazsonyi C, et al. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 2014;195:2-10.
15. Wang H, Cheng G, Du Y, Ye L, Chen W, Zhang L, et al. Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Mol Med Rep 2013;7:947-52.
16. Qiu S, Liu Z, Hou L, Li Y, Wang J, Wang H, et al. Complement activation associated with polysorbate 80 in beagle dogs. Int Immunopharmacol 2013;15:144-9.
17. Moghimi SM, Wibroe PP, Szebeni J, Hunter AC. Surfactant-mediated complement activation in beagle dogs. Int Immunopharmacol 2013;17:33-4.
18. Damas J, Lagneaux D. Dissociation between the effects of zymosan on the systemic and pulmonary vessels of the rat. Br J Pharmacol 1991;104:559-64.
19. Damas J, Remacle-Volon G. Mast cell amines and the oedema induced by zymosan and carrageenans in rats. Eur J Pharmacol 1986;121:367-76.
20. Szebeni J, Bedocs P, Urbanics R, Bunger R, Rosivall L, Toth M, et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Control Release 2012;160:382-7.
21. Kolaczkowska E, Seljelid R, Plytycz B. Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast cell-deficient WBB6F1 mice. J Leukoc Biol 2001;69:33-42.
22. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem 2001;276:22608-13.